Welcome to LookChem.com Sign In|Join Free

CAS

  • or

509-60-4

Post Buying Request

509-60-4 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

509-60-4 Usage

Uses

Dihydromorphine is a metabolite of Hydromorphone (H714650).

Check Digit Verification of cas no

The CAS Registry Mumber 509-60-4 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,0 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 509-60:
(5*5)+(4*0)+(3*9)+(2*6)+(1*0)=64
64 % 10 = 4
So 509-60-4 is a valid CAS Registry Number.
InChI:InChI=1/C17H21NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,13,16,19-20H,3,5-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1

509-60-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Dihydromorphine

1.2 Other means of identification

Product number -
Other names DIHYDROMORPHINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:509-60-4 SDS

509-60-4Relevant articles and documents

Stereoselective reduction method of morphinone compounds

-

Paragraph 0043-0046, (2017/09/02)

The invention discloses a stereoselective reduction method of morphinone compounds. The stereoselective reduction method comprises the step as follows: the morphinone compounds and tetramethylammonium triacetoxyborohydride are subjected to a reaction in an organic solvent in the presence of acid. A reducing agent, namely, tetramethylammonium triacetoxyborohydride, used in the method is convenient to prepare, low in cost, easy to store and non-corrosive to equipment, besides, reaction yield can basically reach about 99%, and de value can reach 98% or higher.

On the selection of an opioid for local skin analgesia: Structure-skin permeability relationships

Musazzi, Umberto M.,Matera, Carlo,Dallanoce, Clelia,Vacondio, Federica,De Amici, Marco,Vistoli, Giulio,Cilurzo, Francesco,Minghetti, Paola

, p. 177 - 185 (2015/05/20)

Recent studies demonstrated that post-herpetical and inflammatory pain can be locally managed by morphine gels, empirically chosen. Aiming to rationalize the selection of the most suitable opioid for the cutaneous delivery, we studied the in vitro penetration through human epidermis of eight opioids, evidencing the critical modifications of the morphinan core. Log P, log D, solid-state features and solubility were determined. Docking simulations were performed using supramolecular assembly made of ceramide VI. The modifications on position 3 of the morphinan core resulted the most relevant in determining both physicochemical characteristics and diffusion pattern. The 3-methoxy group weakened the cohesiveness of the crystal lattice structure and increased the permeation flux (J). Computational studies emphasized that, while permeation is essentially controlled by molecule apolarity, skin retention depends on a fine balance of polar and apolar molecular features. Moreover, ChemPLP scoring the interactions between the opioids and ceramide, correlated with both the amount retained into the epidermis (Qret) and J. The balance of the skin penetration properties and the affinity potency for μ-receptors evidenced hydromorphone as the most suitable compound for the induction of local analgesia.

IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES

-

Page/Page column 25, (2009/01/20)

The present invention is directed to the conversion of a 6-keto morphinan to a 6-alpha-hydroxy morphinan in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source.